Albert Boyd, MD
Family Medicine · Desoto, TXNPI 1679548721
Payments from drug & device makers
Across 126 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$720
- GSK$206
- AstraZeneca$168
- Amgen$157
- Galderma Laboratories, L.p.$141
- Sunovion Pharmaceuticals Inc.$120
- plus $875 from 20 others
What the payments were for
- Food & beverage$2,387100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $720 |
| GSK | 14 | $206 |
| AstraZeneca | 10 | $168 |
| Amgen | 5 | $157 |
| Galderma Laboratories, L.p. | 2 | $141 |
| Sunovion Pharmaceuticals Inc. | 11 | $120 |
| Lilly USA, LLC | 6 | $104 |
| AbbVie | 5 | $91 |
| Abbott | 4 | $89 |
| Pfizer | 4 | $88 |
| Ironwood Pharmaceuticals, Inc | 4 | $81 |
| Dexcom, Inc. | 2 | $63 |
| Corcept Therapeutics | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $37 |
| Itamar Medical Inc | 1 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$121
How this compares
$2,387 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $157,169 |
| EliquisApixaban | 308 | $128,783 |
| RybelsusSemaglutide | 90 | $104,020 |
| JardianceEmpagliflozin | 134 | $92,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $70,946 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $61,127 |
| LinzessLinaclotide | 57 | $56,462 |
| TrulicityDulaglutide | 46 | $47,753 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $46,912 |
| MounjaroTirzepatide | 41 | $41,453 |
| FarxigaDapagliflozin Propanediol | 48 | $34,119 |
| VascepaIcosapent Ethyl | 46 | $30,683 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $29,230 |
| Divalproex Sodium | 316 | $21,369 |
| Spiriva RespimatTiotropium Bromide | 21 | $21,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $720 | $261,189180 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr, Tradjenta, Combivent Respimat | $26 | $149,990209 claims |
| PfizerEliquis | $88 | $128,783308 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $206 | $96,172125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $104 | $89,20687 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $168 | $86,378159 claims |
| AbbVieLinzess | $91 | $56,46257 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $33 | $17,73844 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $120 | $16,37422 claims |
| NovartisEntresto | $18 | $16,23125 claims |
| Johnson & JohnsonXarelto | $29 | $12,78722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Desoto
- Hareshkumar BogharaDesoto$30.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.